Your session is about to expire
← Back to Search
Prevention Strategies for HIV Among At-risk Latinos
N/A
Waitlist Available
Led By Laura R Glasman
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Cis-gender female.
Did not have sex with men or identify as homosexual or bisexual.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up past 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing if a network intervention can help Latino men who have sex with men and transwomen get regular HIV tests and prevent HIV transmission.
Who is the study for?
This trial is for Latino men who have sex with men and transwomen over 18 years old, living in Milwaukee, Cleveland, or Indianapolis. Participants must be able to consent and belong to a network where at least 80% are of Latinx descent. Cisgender females and those not identifying as homosexual or bisexual cannot join.
What is being tested?
The study tests the effectiveness of HIV prevention strategies among friendship networks through regular testing, risk reduction counseling, PrEP awareness, and referrals. It's a randomized controlled trial comparing these interventions within selected communities.
What are the potential side effects?
Since this trial focuses on counseling and education rather than medication or medical procedures, there may not be direct physical side effects; however participants might experience emotional distress or anxiety related to discussing personal behaviors associated with HIV risk.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am a cisgender female.
Select...
I do not identify as homosexual or bisexual nor have sex with men.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ past 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~past 12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mean percentage of PrEP-eligible participants who report having consulted with a provider about PrEP.
Mean percentage of participants who report having had unprotected sex with a casual partner.
Mean percentage of participants who report having tested for HIV in the past 6 months.
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Standard of Care plus Network InterventionExperimental Treatment2 Interventions
Network intervention
Group II: Standard of CareActive Control1 Intervention
HIV counseling and testing
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
HIV counseling and testing
2012
N/A
~490
Find a Location
Who is running the clinical trial?
National Institute of Mental Health (NIMH)NIH
2,928 Previous Clinical Trials
2,744,563 Total Patients Enrolled
Medical College of WisconsinLead Sponsor
633 Previous Clinical Trials
1,181,239 Total Patients Enrolled
Laura R GlasmanPrincipal InvestigatorMedical College of Wisconsin
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a Latinx man who has sex with men or a transgender woman, and I am 18 or older.I am a cisgender female.I do not identify as homosexual or bisexual nor have sex with men.
Research Study Groups:
This trial has the following groups:- Group 1: Standard of Care
- Group 2: Standard of Care plus Network Intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.